Sanofi (Mexico) Today
| SNYN Stock | MXN 1,120 22.00 2.00% |
PerformanceModest
| Odds Of DistressLow
|
Sanofi is trading at 1120.00 as of the 16th of February 2025; that is 2.00 percent increase since the beginning of the trading day. The stock's open price was 1098.0. Sanofi has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat modest performance during the last 90 days. The performance scores are derived for the period starting the 17th of January 2025 and ending today, the 16th of February 2025. Click here to learn more.
It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1 and Aubagio, an immunomodulatory and Lemtrada, a monoclonal antibody for multiple sclerosis. Sanofi was founded in 1973 and is headquartered in Paris, France. The company has 2.47 B outstanding shares. More on Sanofi
Moving together with Sanofi Stock
Moving against Sanofi Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Sanofi Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Sanofi's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Sanofi or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Director | Paul Hudson |
| Business Concentration | Drug Manufacturers - Major, Healthcare (View all Sectors) |
Sanofi (SNYN) is traded on Mexican Exchange in Mexico and employs 58 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 2.22 T. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Sanofi's market, we take the total number of its shares issued and multiply it by Sanofi's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Sanofi operates under Healthcare sector and is part of Drug Manufacturers - Major industry. The entity has 2.47 B outstanding shares.
Sanofi has accumulated about 8.73 B in cash with 10.52 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.5.
Check Sanofi Probability Of Bankruptcy
Ownership AllocationSanofi shows a total of 2.47 Billion outstanding shares. About 89.74 % of Sanofi outstanding shares are held by general public with 10.26 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Sanofi Ownership Details
Sanofi Risk Profiles
Although Sanofi's alpha and beta are two of the key measurements used to evaluate Sanofi's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.8119 | |||
| Semi Deviation | 1.13 | |||
| Standard Deviation | 1.6 | |||
| Variance | 2.56 |
Sanofi Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Sanofi without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Companies Directory Now
Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
| All Next | Launch Module |
Sanofi Corporate Management
Elected by the shareholders, the Sanofi's board of directors comprises two types of representatives: Sanofi inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanofi. The board's role is to monitor Sanofi's management team and ensure that shareholders' interests are well served. Sanofi's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanofi's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roy Papatheodorou | Gen VP | Profile | |
| Josephine Fubara | Chief Care | Profile | |
| Pierre Chancel | Sr Marketing | Profile | |
| Bruno Mnard | Chief officer | Profile | |
| Laurent Gilhodes | Principal Accounting | Profile |
Additional Tools for Sanofi Stock Analysis
When running Sanofi's price analysis, check to measure Sanofi's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi is operating at the current time. Most of Sanofi's value examination focuses on studying past and present price action to predict the probability of Sanofi's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi's price. Additionally, you may evaluate how the addition of Sanofi to your portfolios can decrease your overall portfolio volatility.